PARP Inhibitor
<p>Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer</p>
... combining PARP inhibitor administration with a lower AUC of car- boplatin or administering PARP inhibitors only as main- tenance therapy following treatment for platinum-sensitive relapse may be ...
20
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
... to PARP inhibitors due to the accumulation of SSB in PARP-inhibited cells that would normally be resolved at replication by HRR ...the PARP inhibitor, olaparib in replicating CLL cells ...on ...
14
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
... of PARP inhibitors in human cancers [20], it is important to evaluate the anti-cancer effects of PARP inhibition in ...the PARP inhibitor olaparib and doxorubicin was evaluated in osteosarcoma ...
15
Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
... potent PARP-1, PARP-2, and PARP-3 ...the PARP inhibitor rucaparib as well as future trials and use of rucaparib’s companion diagnostic ...rucaparib, PARP inhibitor, ...
9
PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression
... the PARP inhibitor ABT-888 or PARP-1 depletion increases the sensitivity to ...by PARP-1. Our results demonstrate that both ABT-888 treatment and PARP-1 depletion were able to ...
14
Review Article The ups and downs of DNA repair biomarkers for PARP inhibitor therapies
... of PARP inhibitor as a single agent in the ab- sence of ...active inhibitor of PARP1 and PARP2 with up to 1000-fold selective po- tency in isogenic preclinical models [31, ...study, PARP ...
27
Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor
... of PARP activity in the injured brains. PARP activity can be measured acutely after TBI by the accumulation of poly(ADP-ribose) polymer, the enzy- matic produced of PARP-1 and other PARP ...
11
TITLE: Identification of a PARP Inhibitor Sensitivity Signature in Breast Cancer using A Novel Transcription Factor Activity Array
... When PARP-1 is blocked, backup DNA recombination mechanisms, such as homologous recombination, normally become ...of PARP inhibitors in BRCA- defective cancer cells is thought to lead to unsustainable ...
10
Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer
... the PARP inhibitor, AZ7379, that we utilized in the ...a PARP inhibitor would increase drug delivery to the ...increased PARP inhibition in OVCAR8 tumors (subcutaneous and ...
17
BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor
... Figure 6. AZD5153 improves therapeutic efficacy of the PARP inhibitor, BMN673, in colorectal cancer cells in vivo. Male and female nude mice (n = 6 per group) were orthotopically implanted with HCT116 tumor ...
13
Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status
... Our results differ from those published for the PARP inhibitor ABT-888 by Vilar et al., in 2011 and the PARP inhibitor BMN673 by Gaymes et al., in 2013 [28,29]. Vilar et al. reported that ...
11
Rucaparib: a novel PARP inhibitor for <em>BRCA</em> advanced ovarian cancer
... different PARP inhibitors have been shown to be active, a direct comparative analysis of agents is not ...each PARP inhibitor has its characteristic toxicity ...
13
PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
... Veliparib is another PARP inhibitor developed by AbbVie USA [11]. The FDA awarded veliparib orphan drug status in November 2016 for non-small cell lung cancer. As of 2017, 96 clinical trials involving ...
14
Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy
... EGFR inhibitor and a PARP inhibitor is effective in ovarian cancer A2780 xenografts, and depends on enhanced ...polymerase, PARP, olaparib, tyrosine kinase inhibitor, ovarian cancer, ...
8
Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity
... The majority of PARP inhibitor sensitivity genes identified to date have a known role in DNA double strand break repair (DSBR). In part, the DSB signalling and repair process is controlled by ...
13
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I SPY 2 randomized neoadjuvant setting
... Background: Patients with BRCA1-like tumors correlate with improved response to DNA double-strand break-inducing therapy. A gene expression-based classifier was developed to distinguish between BRCA1-like and ...
9
Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
... Here we provided evidence of the sensitization of SSTR2-expressing human tumor cells and NET tissue slices to PRRT using the PARP inhibitor Olaparib. The knowledge gained in this study will also be ...
12
Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment
... towards PARP inhibition, comparable to loss of BRCA1 in two- and three-dimensional in vitro models, as well as in in vivo xenograft ...of PARP inhibitor response, and consequently offers novel ...
15
The PARP inhibitor: the promises and challenges of targeted breast cancer therapy
... unique inhibitor that targets the PARP zinc binding ...tracking PARP activity. However, controversy over whether this PARP inhibitor was effective came to the attention of researchers ...
15
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
... Fig. 2 A focused CRISPR-Cas9 mutagenesis “ tag, mutate and enrich ” screen identi fi es PARP1 mutations outside the DNA-binding domain that cause PARP inhibitor resistance. a Experimental “ tag, mutate and ...
14